Clinical trials: Cancer Treatment
Multiple Myeloma, Newly Diagnosed
Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients
This single-arm, open-label study aims to determine the efficacy and safety of low-dose, limited-duration teclistamab as a consolidation scheme in newly diagnosed multiple myeloma (NDMM) patients.
- Trial name
- NCT06758375
- Testing
- Low-dose teclistamab
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma
This phase I/II trial studies the best dose and side effects of venetoclax and how well it works in combination with ixazomib and dexamethasone in treating patients with t(11;14) negative multiple myeloma that has come back or…
- Conditions
- Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, t(11;14) Negative
- Trial name
- NCT03856112
- Testing
- Dexamethasone, Ixazomib, Ixazomib Citrate
- Sponsor
- National Cancer Institute (NCI)
CML (Chronic Myelogenous Leukemia)
Ropeginterferon for Treatment Free Remission
Ropeginterferon is a long-acting next-generation mono-pegylated interferon alfa-2b consisting of one isoform produced by PharmaEssentia Co.
- Trial name
- ROPEG (NCT07105319)
- Testing
- Ropeginterferon
- Where
- South Korea
- Volunteers
- 65 people
- Sponsor
- Dong-Wook Kim
Actinic Keratosis of Face and Scalp
Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic Keratosis
The goal of this clinical trial is to show superiority of Veregen® 10% ointment to Placebo measured by complete (100%) clearance of a pre-defined treatment area (TA) following a treatment period of 12 weeks and a 4-weeks…
- Trial name
- EXACT-1 (NCT07137819)
- Testing
- Topical treatment
- Where
- Germany
- Volunteers
- 280 people
- Sponsor
- Aresus Pharma GmbH
Advanced Lung Cancer
A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer
A non-randomized, open, Simon'soptimal2-stage study to evaluate the efficacy and safety of 6MW3211 in patients with advanced Lung Cancer who had failed therapy with PD-1/L1 Inhibitor.
- Trial name
- NCT05431569
- Testing
- 6MW3211
- Volunteers
- 36 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
Irinotecan Followed by Fluorouracil in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of irinotecan followed by fluorouracil in treating patients…
- Trial name
- NCT00024141
- Testing
- fluorouracil, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Diffuse Large B-cell Lymphoma, de Novo DLBCL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
The purpose of this study is to evaluate the efficacy of Pixantrone + Rituximab compared to Gemcitabine + Rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), or follicular grade 3 lymphoma.
- Conditions
- Diffuse Large B-cell Lymphoma, de Novo DLBCL, DLBCL Transformed From Indolent Lymphoma, Follicular Grade 3 Lymphoma
- Trial name
- PIX-R (NCT01321541)
- Testing
- Pixantrone + Rituximab, Gemcitabine + Rituximab
- Where
- 131 sites in United States, Austria and 15 more
- Volunteers
- 312 people
- Sponsor
- CTI BioPharma
Breast Cancer
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00068341
- Testing
- trastuzumab, carboplatin, docetaxel
- Where
- 4 sites in United States
- Volunteers
- 74 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Leukemia
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and…
- Trial name
- NCT00004905
- Testing
- filgrastim, recombinant interferon alfa, cyclophosphamide
- Where
- 3 sites in United States
- Sponsor
- Loyola University
Brain Edema, Brain Tumor
XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
The purpose of this study is to compare the safety and efficacy of XERECEPT® to dexamethasone (Decadron) a common treatment for symptoms of brain swelling (edema).
- Trial name
- NCT00088166
- Testing
- hCRF
- Where
- 34 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Celtic Pharma Development Services
Kidney Cancer
Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Medroxyprogesterone may help shrink or slow the growth of kidney cancer. Interferon may interfere with the growth of tumor cells. Aldesleukin may stimulate white blood cells to kill tumor cells.
- Trial name
- NCT00416429
- Testing
- aldesleukin, recombinant interferon alpha-2a, medroxyprogesterone
- Volunteers
- 456 people
- Sponsor
- Centre Leon Berard
Lung Cancer
Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with surgery may kill more tumor cells.
- Trial name
- NCT00003231
- Testing
- cisplatin, docetaxel, surgical procedure
- Where
- 9 sites in Switzerland
- Volunteers
- 40 people
- Sponsor
- Swiss Cancer Institute
Locally Advanced Colorectal Cancer
Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally Advanced Colorectal Cancer
To explore the efficacy and safety of pembrolizumab in combination with bevacizumab and CapeOX neoadjuvant therapy for the treatment of RAS-mutated, BRAF wild-type, microsatellite-stabilized, locally advanced colorectal cancer.
- Trial name
- NCT06550453
- Testing
- Pabolizumab+ bevacizumab and CapeOX (bevacizumab + oxaliplatin + capecitabine)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- yangjianjun
Relapsed B-Cell Acute Lymphoblastic Leukemia
T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
The purpose of this study is to test the safety of giving the patient special cells made from their own blood called "Modified T-cells".
- Trial name
- NCT01860937
- Testing
- leukapheresis or collection of PBMCs, cyclophosphamide based chemotherapy regimens, modified T cells
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Lymphocytic Leukemia, Follicular Lymphoma
Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia
This study aims to collect clinical data, mainly focused on safety, in the local target population as per the requirement of Korea Ministry of Food and Drug Safety for market authorization.
- Trial name
- NCT03374137
- Testing
- obinutuzumab
- Where
- 17 sites in South Korea
- Volunteers
- 55 people
- Sponsor
- Hoffmann-La Roche
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
RATIONALE: Vaccines made from DNA may make the body build an effective immune response to kill tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best dose of vaccine therapy in treating patients…
- Trial name
- NCT00104845
- Testing
- human gp100 plasmid DNA vaccine, mouse gp100 plasmid DNA vaccine
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Large B Cell Lymphoma
Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients
It is expected that addition of anti-CD20 antibody - ofatumumab would enhance the activity of the etoposide+ifosphamide with mesna+cytarabine+methotrexate+lenograstim or filgrastim (IVAC) regimen.
- Trial name
- PLRG8 (NCT01481272)
- Testing
- Ofatumumab, Etoposide, Ifosfamid
- Where
- 8 sites in Poland
- Volunteers
- 77 people
- Sponsor
- Polish Lymphoma Research Group
Breast Cancer Metastatic
Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer
This is a multicenter, prospective, randomized, open-label, controlled phase II study to test the addition of the CDK4/6 inhibitor ribociclib to anti-hormonal treatment as maintenance therapy in patients with disease control (at…
- Trial name
- AMICA (NCT03555877)
- Testing
- Ribociclib, Anastrozole, Letrozole
- Where
- Germany
- Volunteers
- 56 people
- Sponsor
- GBG Forschungs GmbH
Relapsed B-cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin Lymphoma
A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
This is a prospective, single-arm, open-label, exploratory clinical study of LUCAR-20SP in adult subjects with relapsed/refractory B-cell non-Hodgkin lymphoma.
- Trial name
- NCT06313957
- Testing
- LUCAR-20SP cells
- Where
- 3 sites in China
- Volunteers
- 42 people
- Sponsor
- Peking University Cancer Hospital & Institute
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma
This phase I trial tests the side effects and best dose of TGFbi natural killer (NK) cells (TiNK) when given together with isatuximab for the treatment of patients with multiple myeloma that has come back after a period of…
- Trial name
- NCT06203912
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Elvira Umyarova